![]() ![]() The company was founded in 1997 and is headquartered Dublin, Ireland. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. ![]() Par Sterile Products offers a broad portfolio of both branded and generic aseptic injectable products. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. Including those buyout costs and other one-time items, Endo earned 39 million, or 33 cents a share, on revenue of 335 million, up from 290.3 million a year ago. Product Database Par Pharmaceutical offers an extensive range of prescription products across various therapeutic categories. ![]() The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. 25, 2021 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended Decemand introduced 2021. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Branded Pharmaceuticals segment conducts certain operations in the U.S. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The stock carries a Zacks #3 Rank (Hold rating) in the short run.Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. The Zacks Consensus Estimate has been revised following the company’s guidance and currently hints at earnings of $5.05 per share for 2012. ![]() We believe higher than expected effective tax rate (30.5%-31.5% as opposed to 27% in 2011) and operating expenses are responsible for the weak earnings guidance. The Zacks Consensus Estimate of $3.24 billion is well within the company’s guidance range.Įndo Pharma expects to end 2012 with adjusted earnings in the range of $5.00-$5.20.The guidance is much below the pre-earnings Zacks Consensus Estimate of $5.47. The global market for CNS Therapeutics estimated at US114.9 Billion in the year 2022, is projected to reach a revised size of US199 Billion by 2030, growing at a CAGR of 7.1 over the analysis. The company expects revenues in the range of $3.15-$3.30 billion, well above 2011 levels. 2011 revenues edged past the Zacks Consensus Estimate of $2.71 billion.Īpart from disclosing financial results, Endo Pharma provided guidance for 2012. Interval: 1 Min 0.1045 Compare: Day Range 0.0957 0.1097 Open 0.102 52 Week Range 0.0801 7.0652 Previous Close 0.1046 Average Volume 1.09M Market Cap 24.41M. Revenues were within the guidance range of $2.72-$2.80 billion provided by the company. Revenues climbed 58.7% to $2.73 billion in 2011 driven by impressive performances across all segments at Endo Pharma. DUBLIN, J/PRNewswire/ - Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study. 2011 earnings surpassed the Zacks Consensus Estimate by 8 cents and were above the company’s guidance range of $4.55-$4.65 per share. Endo Internationals earnings are expected to decrease from 0.78 per share to 0.13 per share in the next year, which is a -83.33 change. Costs related to the acquisition of American Medical Systems contributed to the increase.įor full year 2011, Endo Pharma earned $4.69 per share (up 35%). The remaining revenues came from services sales.Īdjusted operating expenses climbed 58.2% to $280 million. Revenues came from the acquisition of American Medical Systems, a leading pelvic-health devices provider, in June 2011. Revenues from devices sales came in at $142.0 million in the reported quarter. Endo reported earnings of 79 million, or 67. We remind investors that Qualitest Pharmaceuticals was purchased by Endo Pharma in 2010 for $1.2 billion in cash. Endo Pharmaceuticals (Nasdaq: ENDP) and American Medical Systems (AMS) (Nasdaq: AMMD) announced today that they have entered into a definitive agreement under which Endo will acquire AMS, a. Endo Pharmaceuticals says its revenue and pre-charge earnings grew in the first quarter on strong generic sales and its acquisition of Indevus. Revenues from the segment were aided by the inclusion of results from Qualitest Pharmaceuticals (a generic company). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |